Navigation Links
WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
Date:7/30/2010

SHANGHAI, July 30 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2010 on Monday, August 2, 2010, before the U.S. market opens.

(Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations section of its website at http://www.wuxiapptec.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 10:00 am (Eastern) / 7:00 am (Pacific) / 10:00 pm (Beijing/Shanghai/Hong Kong) on Monday, August 2, 2010, to discuss its second-quarter 2010 financial results and recent business activities. The conference call may be accessed by calling:

    United States: 1-866-519-4004
    China (Landline): 800-819-0121
    China (Mobile): 400-620-8038
    Hong Kong: 800-930-346
    United Kingdom: 0-808-234-6646
    International: +65-6723-9381
    Conference ID: 90840146
    Web PIN: 8656

    A replay will be available two hours after the call's completion at:

    United States: 1-866-214-5335
    China North: 10-800-714-0386
    China South: 10-800-140-0386
    Hong Kong: 800-901-596
    United Kingdom: 0-800-731-7846
    International: +61-2-8235-5000
    Passcode: 90840146

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     Phone: +1-201-585-2048
     Email: ir@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
2. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
3. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
6. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
7. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
8. WuXi PharmaTech Announces First-Quarter 2010 Results
9. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
10. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
11. China Nepstar Chain Drugstore Reschedules First Quarter 2010 Results to May 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017 In China ... is where the Upgrade of China,s ... 13th Five-Year Plan for Economic and Social Development of ... Five-Year Plan), and the state council of the ... national strategic emerging industry development plan, identifying medical devices as ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
(Date:1/18/2017)... , Jan. 18, 2017  Robust competition ... rebates and discounts on medicine prices, according to a ... (BRG). The study is among the first to examine ... companies, generic manufacturers, pharmacy benefit managers (PBMs), health plans ... "The BRG study is the first to show what ...
Breaking Medicine Technology:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Fischell Department of Bioengineering are collaborating on a research project focused on multiple ... the project seeks to use nanotechnology to control the disease without compromising normal ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for ... V, its official endurance training and fundraising team, to compete in the Boston Marathon ... those inspired to finish the world’s oldest annual marathon to join Team V and ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, ... and business owners in central Maryland and the DC region, is inaugurating a charity ... 787,000 people nationally every year, making it the #1 killer in America. However, heart ...
(Date:1/18/2017)... ... January 18, 2017 , ... Dr. Farhan Qureshi is an esteemed dentist who ... modern dental practice has two convenient office locations in Alexandria and Arlington, Virginia. Recently, ... for the Alexandria area. This award confirms the fact that Dr. Qureshi’s patients ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Hear the World Foundation, ... the donation of cochlear implants. In February 2017, the first three children with ... chance of leading an independent life. This engagement builds on the support the ...
Breaking Medicine News(10 mins):